$GMED
GLOBUS MEDICAL INC Stock $gmed

$gmed Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000123783117000042 Filed on November 09, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$176.0M	$151.7M	$135.7M
YoY Change	16.13%	11.86%	-0.98%
Cost Of Revenue	$40.90M	$36.80M	$31.45M
YoY Change	4.87%	16.99%	-4.48%
Gross Profit	$135.2M	$114.9M	$104.2M
YoY Change	20.06%	10.31%	0.13%
Gross Profit Margin	76.79%	75.75%	76.81%
Selling, General & Admin	$73.00M	$63.36M	$54.21M
YoY Change	20.07%	16.89%	3.9%
% of Gross Profit	54.0%	55.12%	52.02%
Research & Development	$11.40M	$10.89M	$10.27M
YoY Change	-16.18%	6.06%	10.97%
% of Gross Profit	8.43%	9.47%	9.85%
Depreciation & Amortization	$8.300M	$10.90M	$7.800M
YoY Change	-52.02%	39.74%	27.87%
% of Gross Profit	6.14%	9.48%	7.49%
Operating Expenses	$86.60M	$79.15M	$66.55M
YoY Change	13.5%	18.94%	4.98%
Operating Profit	$48.58M	$35.80M	$37.65M
YoY Change	33.87%	-4.93%	-7.44%
Interest Expense	$2.100M	$1.400M	$1.100M
YoY Change	250.0%	27.27%	1000.0%
% of Operating Profit	4.32%	3.91%	2.92%
Other Income/Expense, Net	$200.0K	$1.562M	$1.205M
YoY Change	0.0%	29.63%	376.28%
Pretax Income	$50.60M	$37.36M	$38.86M
YoY Change	38.63%	-3.86%	-5.06%
Income Tax	$15.20M	$11.77M	$12.63M
% Of Pretax Income	30.04%	31.5%	32.5%
Net Earnings	$24.38M	$25.59M	$26.23M
YoY Change	0.32%	-2.42%	-0.96%
Net Earnings / Revenue	13.85%	16.86%	19.33%
Basic Earnings Per Share	$0.25	$0.27	$0.27
Diluted Earnings Per Share	$0.25	$0.26	$0.27
COMMON SHARES
Basic Shares Outstanding	96.38M shares	96.32M shares	95.74M shares
Diluted Shares Outstanding		97.85M shares	96.49M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$373.7M	$337.7M	$257.9M
YoY Change	28.73%	30.94%	8.09%
Cash & Equivalents	$118.8M	$90.23M	$90.19M
Short-Term Investments	$254.9M	$182.8M	$167.7M
Other Short-Term Assets	$11.20M	$9.400M	$12.10M
YoY Change	-25.33%	-22.31%	-84.16%
Inventory	$108.4M	$111.5M	$115.6M
Prepaid Expenses
Receivables	$116.7M	$94.48M	$86.71M
Other Receivables	$10.40M	$10.50M	$5.900M
Total Short-Term Assets	$620.3M	$563.6M	$478.2M
YoY Change	20.74%	17.85%	-5.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$143.2M	$134.2M	$127.1M
YoY Change	15.24%	5.61%	19.69%
Goodwill	$123.9M	$119.3M	$110.3M
YoY Change	16.96%	8.18%	19.88%
Intangibles	$78.66M	$87.65M	$67.44M
YoY Change	27.47%	29.98%	100.5%
Long-Term Investments	$56.10M	$58.90M	$64.50M
YoY Change	-7.12%	-8.68%	4.88%
Other Assets	$7.947M	$8.280M	$1.015M
YoY Change	756.36%	715.76%	-3.24%
Total Long-Term Assets	$458.2M	$473.6M	$423.5M
YoY Change	10.7%	11.82%	43.89%
TOTAL ASSETS
Total Short-Term Assets	$620.3M	$563.6M	$478.2M
Total Long-Term Assets	$458.2M	$473.6M	$423.5M
Total Assets	$1.079B	$1.037B	$901.7M
YoY Change	16.26%	15.02%	12.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.04M	$16.55M	$13.94M
YoY Change	43.31%	18.78%	-14.81%
Accrued Expenses	$52.59M	$46.61M	$43.29M
YoY Change	13.35%	7.67%	-32.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$93.07M	$74.93M	$65.81M
YoY Change	16.5%	13.86%	-30.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.474M	$1.786M	$1.784M
YoY Change	36.01%	0.11%	-47.53%
Total Long-Term Liabilities	$2.474M	$1.786M	$1.784M
YoY Change	36.01%	0.11%	-47.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$93.07M	$74.93M	$65.81M
Total Long-Term Liabilities	$2.474M	$1.786M	$1.784M
Total Liabilities	$110.7M	$101.9M	$91.62M
YoY Change	15.87%	11.21%	-27.71%
SHAREHOLDERS EQUITY
Retained Earnings	$736.2M	$711.9M	$604.6M
YoY Change	17.07%	17.74%	24.16%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$967.8M	$935.3M	$810.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.079B	$1.037B	$901.7M
YoY Change	16.26%	15.02%	12.62%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	$24.38M	$25.59M	$26.23M
YoY Change	0.32%	-2.42%	-0.96%
Depreciation, Depletion And Amortization	$8.300M	$10.90M	$7.800M
YoY Change	-52.02%	39.74%	27.87%
Cash From Operating Activities	$44.90M	$34.80M	$42.70M
YoY Change	70.72%	-18.5%	41.86%
INVESTING ACTIVITIES
Capital Expenditures	-$13.40M	-$12.80M	-$6.600M
YoY Change	-5.63%	93.94%	-42.61%
Acquisitions
YoY Change
Other Investing Activities	-$4.000M	-$22.30M	-$39.60M
YoY Change	-92.78%	-43.69%	250.44%
Cash From Investing Activities	-$17.40M	-$35.10M	-$46.20M
YoY Change	-75.0%	-24.03%	102.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-100.0K	1.000M	800.0K
YoY Change	-97.14%	25.0%	-52.94%
NET CHANGE
Cash From Operating Activities	44.90M	34.80M	42.70M
Cash From Investing Activities	-17.40M	-35.10M	-46.20M
Cash From Financing Activities	-100.0K	1.000M	800.0K
Net Change In Cash	27.40M	700.0K	-2.700M
YoY Change	-158.55%	-125.93%	-130.0%
FREE CASH FLOW
Cash From Operating Activities	$44.90M	$34.80M	$42.70M
Capital Expenditures	-$13.40M	-$12.80M	-$6.600M
Free Cash Flow	$58.30M	$47.60M	$49.30M
YoY Change	43.95%	-3.45%	18.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001237831
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96376106	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	GLOBUS MEDICAL INC
CY2016Q4	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	734000	USD
CY2017Q3	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	4150000	USD
CY2016Q3	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-2000	USD
	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-5003000	USD
CY2017Q3	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	0	USD
	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-5234000	USD
CY2016Q4	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	14108000	USD
CY2017Q3	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	9742000	USD
CY2016Q4	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	5972000	USD
CY2017Q3	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	10778000	USD
CY2016Q3	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	0	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	0	USD
CY2017Q3	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	0	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	4871000	USD
CY2016Q3	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	259000	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	2696000	USD
CY2017Q3	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	197000	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	1008000	USD
CY2016Q3	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	0	USD
	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	0	USD
CY2017Q3	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	-15000	USD
	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	27000	USD
CY2016Q4	gmed	Intangible Assets Gross IntangibleAssetsGross	68431000	USD
CY2017Q3	gmed	Intangible Assets Gross IntangibleAssetsGross	100075000	USD
CY2016Q3	gmed	Non Cash Settlement Of Contingent Consideration NonCashSettlementOfContingentConsideration	-3110000	USD
	gmed	Non Cash Settlement Of Contingent Consideration NonCashSettlementOfContingentConsideration	-4632000	USD
CY2017Q3	gmed	Non Cash Settlement Of Contingent Consideration NonCashSettlementOfContingentConsideration	0	USD
	gmed	Non Cash Settlement Of Contingent Consideration NonCashSettlementOfContingentConsideration	0	USD
	gmed	Number Of Product Categories NumberOfProductCategories	2
	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	400000	USD
	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	5234000	USD
CY2017Q3	gmed	Prepaidroyalty Prepaidroyalty	9000000	USD
CY2017Q3	gmed	Share Based Compensation Number Of Stock Plans ShareBasedCompensationNumberOfStockPlans	3
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17472000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	16553000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	91983000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	94484000	USD
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1911000	USD
CY2017Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2023000	USD
CY2017Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2500000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46401000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46609000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4671000	USD
CY2017Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2360000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	166711000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	191386000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1958000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1760000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8642000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6178000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	211725000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	229475000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10807000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2747000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8437000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3596000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10659000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2771000	USD
CY2017Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3725000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	884000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1673000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2080000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5671000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5457000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5378000	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2611000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3462000	shares
CY2016Q4	us-gaap	Assets Assets	927637000	USD
CY2017Q3	us-gaap	Assets Assets	1037160000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	513766000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	563562000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	157673000	USD
CY2017Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	182804000	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	60444000	USD
CY2017Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	58884000	USD
CY2016Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1192000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1347000	USD
CY2017Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	285000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1290000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1011000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	26617000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	22531000	USD
CY2016Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19678000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19849000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	20339000	USD
CY2017Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	20521000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3700000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4500000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60152000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90192000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132639000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154855000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	30040000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22216000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	785000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95929916	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96366450	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95929916	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96366450	shares
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	26203000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	80241000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25285000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	85436000	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	31453000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	95703000	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	36798000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	109597000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1356000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	815000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	30638000	USD
CY2017Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	36127000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	7876000	USD
CY2017Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	14405000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21536000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33773000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.84
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.86
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.83
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2324000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	778000	USD
CY2016Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.325
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.337
CY2017Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.315
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.305
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23214000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22599000	USD
CY2016Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	65000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	205000	USD
CY2017Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	50000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	148000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-1500000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	1500000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6725000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12422000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	284000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	83000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-315000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	681000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	105926000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	119273000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	104198000	USD
	us-gaap	Gross Profit GrossProfit	316701000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	114946000	USD
	us-gaap	Gross Profit GrossProfit	350346000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	38855000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	120802000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	37357000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	119328000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12628000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40759000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11766000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36356000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	37009000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	49008000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3800000	USD
CY2017Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10527000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3426000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-344000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3111000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2200000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	6643000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-6709000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-30178000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-9377000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6609000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6956000	USD
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	25000000	USD
	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7332000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	974000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-25642000	USD
	us-gaap	Interest Paid InterestPaid	34000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-477000	USD
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	753000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	829000	shares
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1531000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1447000	shares
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	61706000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	87653000	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	795000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1893000	USD
CY2017Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1738000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4746000	USD
	us-gaap	Interest Paid InterestPaid	23000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	88688000	USD
CY2017Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	80514000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	112692000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	111462000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	13257000	USD
CY2017Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	20454000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	10747000	USD
CY2017Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	10494000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	6919000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	8158000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	3067000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	2258000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	95559000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	101896000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	927637000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1037160000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79892000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	74927000	USD
	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	LIBOR
CY2016Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	3056000	USD
CY2017Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	2537000	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	2780000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4028000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1709000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-93145000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-94969000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	121481000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	114698000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	26227000	USD
	us-gaap	Net Income Loss NetIncomeLoss	80043000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	25591000	USD
	us-gaap	Net Income Loss NetIncomeLoss	82972000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	35795000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	113480000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10836000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	30000000	USD
CY2017Q3	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	29167000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	66548000	USD
	us-gaap	Operating Expenses OperatingExpenses	198282000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	79151000	USD
	us-gaap	Operating Expenses OperatingExpenses	236866000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	37650000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	118419000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11429000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	928000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8280000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	141000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	79000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-313000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2314000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	174000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	2466000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-24000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	198000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-306000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2464000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-165000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	119000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	150000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1819000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1786000	USD
CY2016Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	126000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	407000	USD
CY2017Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	139000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	421000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1205000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2383000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1562000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5848000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	76068000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	31501000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	223623000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	203609000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26701000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37878000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14502000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9430000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	211138000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	166453000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	47109000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	11566000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4428000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6943000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	124229000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	134214000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	320000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1135000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	24000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-2000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10265000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30889000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10887000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32266000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	477000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	628899000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	711871000	USD
CY2016Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	6946000	USD
CY2017Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	6071000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	135651000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	412404000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	151744000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	459943000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	54207000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	161317000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	63362000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	194859000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8437000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10659000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4269000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.46
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2760000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7386000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1264000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6024000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	410000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2223000	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.76
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.66
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.81
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	63708000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7741000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9117000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.08
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.79
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	25.73
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	19887000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4849000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.07
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	23.79
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.62
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2812000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	8642000	USD
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	3646000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10807000	USD
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	43821000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M0D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y8M12D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	437000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6943000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	832078000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	935264000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96492000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96404000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97849000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97607000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95739000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95575000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96318000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96160000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, write-down for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results. </font></div></div>

Files In Submission

Name	View Source	Status
0001237831-17-000042-index-headers.html	Edgar Link	pending
0001237831-17-000042-index.html	Edgar Link	pending
0001237831-17-000042.txt	Edgar Link	pending
0001237831-17-000042-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gmed-20170930.xml	Edgar Link	completed
gmed-20170930.xsd	Edgar Link	pending
gmed-20170930_cal.xml	Edgar Link	unprocessable
gmed-20170930_def.xml	Edgar Link	unprocessable
gmed-20170930_lab.xml	Edgar Link	unprocessable
gmed-20170930_pre.xml	Edgar Link	unprocessable
gmed9301710q.htm	Edgar Link	pending
gmed93017ex311.htm	Edgar Link	pending
gmed93017ex312.htm	Edgar Link	pending
gmed93017ex32.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GMED
GLOBUS MEDICAL INC Stock $gmed

2017 Q4 Form 10-Q Financial Statement

#000123783117000042 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED GLOBUS MEDICAL INC Stock $gmed

2017 Q4 Form 10-Q Financial Statement

#000123783117000042 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED
GLOBUS MEDICAL INC Stock $gmed